Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ortiz, Mayra
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer	Recruiting	3	400	Europe, Canada, Japan, US, RoW	tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil	Seagen Inc., Merck Sharp & Dohme LLC	Colorectal Neoplasms	08/25	04/28
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	Active, not recruiting	2/3	700	US	GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin	Gritstone bio, Inc.	Colorectal Neoplasms	03/27	03/27
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma	Completed	2	55	US	TT-00420	TransThera Sciences (Nanjing), Inc.	Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration	02/24	02/24
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer	Active, not recruiting	2	27	US	Oxaliplatin, Irinotecan, Leucovorin, Panitumumab	Criterium, Inc., Amgen	Colorectal Cancer Metastatic	12/24	01/25
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	2	102	Europe, US, RoW	ZN-c3, azenosertib	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	04/25	10/25